Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11827966 | 0.90 | MMP12 (0.54) | TSHRMMEHTT | |
| SCHEMBL10420113 | 0.89 | GRIK1 (0.50) | CTSCPPARGPPARASMN1; SMN2 | |
| SCHEMBL4397838 | 0.87 | TSHR (0.45) | CTSCTSHRMEN1HTTKMT2A | |
| SCHEMBL10419286 | 0.86 | MAPT (0.50) | SMN1; SMN2 | |
| SCHEMBL4397845 | 0.86 | MAPT (0.50) | SMN1; SMN2 | |
| SCHEMBL28747136 | 0.84 | PPARG (0.47) | CTSCPPARGPPARA | |
| SCHEMBL4695604 | 0.83 | CTSC (0.50) | CTSCCNR2TSHRMEN1HTT | |
| SCHEMBL4837691 | 0.82 | CTSC (0.49) | CTSCCNR2TSHRANPEPMEN1 | |
| SCHEMBL16672942 | 0.81 | ERAP1 (0.46) | CNR2TSHRKEAP1ANPEPERAP1 | |
| SCHEMBL1344165 | 0.81 | CYP1A2 (0.55) | CTSCMMECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3956297-B1 | PROCESS FOR PREPARING CYANOACETATES | HENKEL AG & CO KGAA (DE) | 2024-09-04 | — | — | EP | claimed |
| EP-3956293-B1 | PROCESS FOR PREPARING CYANOACETATES | HENKEL AG & CO KGAA (DE) | 2024-08-07 | — | — | EP | claimed |
| CN-115151527-A | Process for the preparation of cyanoacetic esters | 汉高股份有限及两合公司 | 2022-10-04 | — | — | CN | claimed |
| CN-113710647-A | Process for preparing cyanoacetic acid esters | 汉高知识产权控股有限责任公司 | 2021-11-26 | — | — | CN | claimed |
| CN-113692400-A | Process for preparing cyanoacetic acid esters | 汉高知识产权控股有限责任公司 | 2021-11-23 | — | — | CN | claimed |
| US-20250304529-A1 | BIOBASED CYANOACRYLATE COMPOUND | BOSTIK SA (FR) | 2025-10-02 | — | — | US | disclosed |
| EP-4532465-A1 | BIOBASED CYANOACRYLATE COMPOUND | Bostik SA (FR) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023232948-A1 | BIOBASED CYANOACRYLATE COMPOUND | BOSTIK SA (FR) | 2023-12-07 | — | — | WO | disclosed |
| EP-4286369-A1 | BIOBASED CYANOACRYLATE COMPOUND | Bostik SA (FR) | 2023-12-06 | — | — | EP | disclosed |
| CN-115151527-A | Process for the preparation of cyanoacetic esters | 汉高股份有限及两合公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-110114337-A | The method for preparing electron deficient olefins | 汉高知识产权控股有限责任公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-110099894-A | The method for preparing electron deficient olefins precursor | 汉高知识产权控股有限责任公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-2527350-B1 | Method for preparing phosphine butadiene ligands, complexes thereof with copper and the use of same in catalysis | CENTRE NAT RECH SCIENT (FR) | 2015-06-03 | — | — | EP | disclosed |
| EP-2147004-A2 | METHOD FOR THE PREPARATION OF PHOSPHINE BUTADIENE LIGANDS, COMPLEXES THEREOF WITH COPPER AND USE THEREOF IN CATALYSIS | Centre National De La Recherche Scientifique-CNRS (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008129407-A2 | METHOD FOR THE PREPARATION OF PHOSPHINE BUTADIENE LIGANDS, COMPLEXES THEREOF WITH COPPER AND USE THEREOF IN CATALYSIS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-10-30 | — | — | WO | disclosed |
| EP-0787116-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | Akzo Nobel N.V. (NL) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996011894-A1 | PROCESS FOR SEPARATING ENANTIOMERS FROM A RACEMIC MIXTURE | AKZO NOBEL N.V. (NL) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304529-A1 | BIOBASED CYANOACRYLATE COMPOUND | BAP1, CBR1, CBR3 | CTSC 4411/4885CNR2 1982/4885TSHR 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.